Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5
Onconova Therapeutics, Inc. (ONTX)
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.onconova.com/investor-overview
Company Research
Source: GlobeNewswire
HanX to commercialize in Greater China: Onconova retains rights in rest of the worldHanX will fund studies towards Investigational New Drug (IND) applications in both the US and ChinaAgreement includes licensing fee, customary milestone payments and royalties on sales NEWTOWN, Pa., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced the signing of a license and collaboration agreement with HanX Biopharmaceuticals, Inc., a company focused on development of novel oncology products, for the further development, registration and commercialization of ON 123300 in China. ON 123300 is a first-in-class dual inhibitor of CDK4/6 + ARK5, which is currently in advanced pre-clinical development. This compound has the potential to overcome the limitations of current generation CDK
Show less
Read more
Impact Snapshot
Event Time:
ONTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONTX alerts
High impacting Onconova Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONTX
News
- Onconova Therapeutics, Inc. (NASDAQ: ONTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Onconova Therapeutics, Inc. (NASDAQ: ONTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- We Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024 [Yahoo! Finance]Yahoo! Finance
- Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024GlobeNewswire
ONTX
Earnings
- 11/14/23 - Beat
ONTX
Sec Filings
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- 3/14/24 - Form 144
- ONTX's page on the SEC website